Related Experiment Video
Updated: May 1, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect
Paula Lopez-Serra1, Miguel Marcilla2, Alberto Villanueva3
1Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, 08908 Catalonia, Spain.
Abstract:
Cancer cells possess aberrant proteomes that can arise by the disruption of genes involved in physiological protein degradation. Here we demonstrate the presence of promoter CpG island hypermethylation-linked inactivation of DERL3 (Derlin-3), a key gene in the endoplasmic reticulum-associated protein degradation pathway, in human tumours. The restoration of in vitro and in vivo DERL3 activity highlights the tumour suppressor features of the gene. Using the stable isotopic labelling of amino acids in cell culture workflow for differential proteome analysis, we identify SLC2A1 (glucose transporter 1, GLUT1) as a downstream target of DERL3. Most importantly, SLC2A1 overexpression mediated by DERL3 epigenetic loss contributes to the Warburg effect in the studied cells and pinpoints a subset of human tumours with greater vulnerability to drugs targeting glycolysis.
Insights
Cancer cells can inactivate the DERL3 gene through epigenetic changes, leading to increased glucose transporter GLUT1. This promotes the Warburg effect and makes tumors more susceptible to glycolysis-targeting drugs.
Area of Science:
- Molecular biology
- Cancer research
- Epigenetics
Background:
- Aberrant proteomes in cancer cells often result from disrupted protein degradation pathways.
- The endoplasmic reticulum-associated protein degradation (ERAD) pathway is crucial for maintaining proteostasis.
Purpose of the Study:
- To investigate the role of DERL3 (Derlin-3) gene inactivation in human tumors.
- To identify downstream targets of DERL3 and their contribution to cancer phenotypes.
Main Methods:
- Analysis of promoter CpG island hypermethylation to detect DERL3 inactivation.
- Proteome analysis using stable isotopic labeling of amino acids in cell culture (SILAC).
- In vitro and in vivo experiments to restore DERL3 activity.
Main Results:
- Promoter CpG island hypermethylation inactivates DERL3 in human tumors.
- DERL3 inactivation leads to overexpression of SLC2A1 (glucose transporter 1, GLUT1).
- Restoring DERL3 activity demonstrated its tumor suppressor function.
Conclusions:
- Epigenetic silencing of DERL3 contributes to the Warburg effect via GLUT1 upregulation.
- This epigenetic alteration identifies a subset of tumors vulnerable to glycolysis inhibitors.
- DERL3 acts as a tumor suppressor by regulating proteostasis and glucose metabolism.
More Related Videos
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Abnormal Proliferation
Lysosomal Hydrolases
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
Translation
Translation Produces the Building Blocks of Life
Proteins are...

